Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - BI1
BI1 Details
Status: Closed 
Activation Date: 2008MAR19
Closing Date: 2009JUL14
Phase: III 

Description: Phase III Trial of Combined Gemcitabine Plus Capecitabine Chemotherapy Versus Gemcitabine Alone in Advanced Biliary Cancer. 

Eligibility: Patients with histologically/cytologically proven adenocarcinoma of the biliary tree (intra and extra-hepatic biliary ducts or gallbladder) that is either unresectable or metastatic. Patient must have evidence of disease but measurable disease is not required. They may not have received previous chemotherapy for advance or metastatic disease unless used as a radiosensitizer. Must have life expectancy > or = 12 weeks. 

Objective: Primary: Overall survival. Secondary: Progression-free survival, response rates (CR and PR), rate of stable disease (SD), rate of disease control (CR, PR and SD), response duration, quality of life, toxicity 

Participation: Open to member centres 

Lay Description: The purpose of this study is to find out whether it is better to receive a capecitabine in combination with gemcitabine, or better to receive only gemictabine for biliary cancer. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
GASTRO-INTESTINAL BI1 19 0 1 1
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
GASTRO-INTESTINAL BI1 19 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
GASTRO-INTESTINAL BI1 19 0 0 0 0 0 0 0 0